The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

Medera, Inc., (“Medera”), a clinical-stage biotechnology company, announced today that the management team will participate ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.

Separately, Rakovina Therapeutics expects to receive the first synthesized drug candidates from its second AI-driven drug ...

Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.

Johnson & Johnson is contributing $1 million to support the development of curricula and modernization of training and lab ...